Secukinumab: a new treatment option for psoriatic arthritis by Mease, Philip & McInnes, Iain B.
REVIEW
Secukinumab: A New Treatment Option for Psoriatic
Arthritis
Philip Mease . Iain B. McInnes
Received: March 1, 2016 / Published online: April 23, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Psoriatic arthritis (PsA) is an
immune-mediated chronic inflammatory
arthropathy associated with impaired physical
function and reduced quality of life. Biologic
therapies that target tumor necrosis factor
(anti-TNF) have significantly improved clinical
outcomes. Partial, non- and transient responses
remain common comprising significant unmet
clinical need. New therapies with novel modes
of action are urgently required.
Objectives: The interleukin (IL)-17 pathway has
recently been attributed a critical role in the
pathogenesis of spondyloarthritides. Herein, we
review data from clinical studies with
secukinumab, a novel fully human IgG1j
anti-IL-17A monoclonal antibody (mAb), in
patients with active PsA.
Results: Across two pivotal phase 3 studies,
secukinumab provided significant and
sustained reductions in the signs and
symptoms of PsA, inhibition of radiographic
progression, and improved patient-reported
outcomes and measures of quality of life. The
primary efficacy endpoint, a C20%
improvement from baseline according to the
American College of Rheumatology 20 (ACR20)
response at Week 24, was significantly higher in
patients treated with secukinumab compared
with placebo, with improvements sustained
through at least 52 weeks. Clinical benefits
were seen with secukinumab regardless of
concomitant methotrexate treatment and in
patients who were either anti-TNF-naı¨ve or who
were inadequate responders to anti-TNF
therapy. Secukinumab was well-tolerated, with
a safety profile consistent with that previously
reported in psoriasis trials. The most common
adverse events were nasopharyngitis, upper
respiratory tract infections, and headache.
Conclusion: Secukinumab offers an effective
new addition to the available treatment
options for PsA. Regulatory submissions have
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been filed worldwide, with the first approvals
recently obtained in Japan and Europe. Future
studies are required to define the optimal
timing and strategic use of this novel
treatment modality.
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INTRODUCTION
Psoriatic arthritis (PsA) is an immune-mediated
chronic inflammatory arthropathy-associated
with psoriasis [1]. The occurrence of PsA has
been estimated at between 6% and 42% of
patients afflicted with psoriasis [2–6], which
occurs in 1–3% of the population [7–9]. The
clinical manifestations of PsA include arthritis,
enthesitis, dactylitis, spondylitis, psoriasis, and
nail disease, with approximately 50% of patients
also experiencing erosive joint damage within
the first 2 years [10]. Thus, therapeutic principles
should comprise management of disease in each
tissue compartment, with the ultimate goal of
impeding disease progression and maximizing
function over time [11, 12].
Until the adventof tumornecrosis factor (TNF)
inhibitors, treatment for PsA focused largely on
the use of non-steroidal anti-inflammatory drugs
(NSAIDs) and conventional disease-modifying
anti-rheumatic drugs (DMARDs) despite a dearth
of evidence showing their efficacy in clinical trials
[13]. Nevertheless, clinical experience suggests
that these agents are effective at reducing
inflammation and treating some symptoms and
signs and they remain the recommendedfirst-line
treatment option for patients with active PsA
across several current international guidelines
[11, 12].
The development of anti-TNF therapies
revolutionized the treatment of PsA, offering
an effective biologic treatment for patients who
showed a lack of efficacy and/or toxicity with
NSAIDs and DMARDs [11, 14–16]. Extensive
evidence accrued with several agents across
numerous clinical trials and registries shows
that anti-TNF agents are efficacious in the
treatment of PsA. However, a number of
unmet needs remain; for example, some
patients have an inadequate response to, or
intolerance of anti-TNF agents, long-term
therapy with these agents is associated with
decreasing drug survival rates, and the increased
risk of infection may be of concern to some
patients [16–18].
Consequently, therapies with differing
modes of action, including agents that were
developed for the treatment of other rheumatic
diseases (e.g., abatacept, rituximab,
tocilizumab), have been tested for potential
efficacy in PsA [16, 19]. Some of these agents,
such as the phosphodiesterase 4 (PDE4)
inhibitor apremilast [20] and the interleukin
(IL)-12/23 inhibitor ustekinumab [21], have
demonstrated efficacy in clinical trials and are
approved for use in PsA in the majority of
developed countries. Nevertheless, because of
inadequate efficacy, intolerance, or safety issues
new treatments with alternative modes of
action continue to be sought. Recently,
genome-wide association studies, together
with translational immunology analyses, have
identified several novel molecular cascades
involved in the pathogenesis of psoriasis and
PsA, including particularly the IL-17 pathway
[22].
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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THE IL-17 PATHWAY IN PSA
The inflammatory cytokine IL-17 is part of a
family of six homodimeric cytokines (IL-17A–F)
and one heterodimer (IL-17A/F), that in turn
signal via five IL-17 receptors (IL-17RA–E, in
turn functioning as heterodimers). Discrete
IL-17 family members elaborate functional and
immunological differences [23–26]. IL-17A is a
dimeric glycoprotein that functions in both the
innate and adaptive immune responses, and
specifically mediates effects in antibacterial and
fungal immunity and tissue repair [23, 27]. The
effects of the other members of the IL-17 family
are less well characterized, although evidence
suggests they are involved in antimicrobial
defense through the innate immune response.
IL-17A is produced by a range of immune cells,
including especially Th17 cells and Type 3
innate lymphoid cells and can affect the
function of several cell types such as
neutrophils, keratinocytes, fibroblast-like
synoviocytes, endothelial cells, chondrocytes,
and osteoblasts [28–30]. Activation of these cells
results in the release of further
pro-inflammatory cytokines and chemokines,
which aside from promoting inflammation,
drive other pathological processes including
hyperproliferation, matrix destruction, vessel
activation, bone erosion, and cartilage damage
[28–30].
The IL-17 pathway has been shown to play
an important role in the pathology of PsA [18,
31]. Inflammation in PsA is characterized by
synovial tissue enriched by expression of IL-17A
and IL-17RA [32]. Whereas CD4? T cells express
IL-17A, IL-17A-producing CD8? T cells are more
abundant in the synovial fluid of patients with
PsA, compared to healthy individuals, and the
levels of these cells positively correlate with
measures of disease activity and joint damage
progression [33]. Evidence from preclinical
studies further supports the contribution of
the IL-17 pathway to PsA pathogenesis. Local
overexpression of IL-17 during
collagen-induced arthritis in mice is associated
with increased synovial inflammation and joint
destruction [34], while elevated expression of
IL-23 in a murine model induced a population
of IL-23R?CD3?CD4-CD8- entheseal resident
T cells to produce inflammatory mediators
including IL-17 and IL-22, which was
accompanied by histologic evidence of
enthesitis [34, 35].
Consequently, biological therapies targeting
the IL-17 pathway, including antibodies against
IL-17A (secukinumab and ixekizumab) and
IL-17RA (brodalumab), have been extensively
evaluated in psoriasis, PsA, and other
spondyloarthritides [29].
SECUKINUMAB: MODE
OF ACTION, PHARMACOKINETICS,
AND PHARMACODYNAMICS
Secukinumab is a fully human IgG1j
anti-IL-17A monoclonal antibody (mAb),
which targets the function of IL-17A [36].
Secukinumab selectively binds to and
neutralizes IL-17A, inhibiting its interaction
with IL-17 receptors expressed on
keratinocytes, fibroblast-like synoviocytes,
endothelial cells, chondrocytes, and
osteoblasts. As a result, secukinumab inhibits
downstream inflammatory pathways implicated
in autoimmune and inflammatory diseases,
while leaving other immune functions
undisturbed (Fig. 1) [29, 36–39].
In patients with psoriasis, serum levels of total
IL-17A (free and secukinumab-bound IL-17A)
increase to plateau serum concentrations after
administration of secukinumab. Following
cessation of treatment, serum levels slowly
decrease reflecting the kinetics of clearance of
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secukinumab-bound IL-17A. No significant
changes in IL-17F are seen after secukinumab
treatment, indicating that secukinumab
selectively binds to and neutralizes free IL-17A
[40]. In patients with plaque psoriasis, infiltrating
epidermal neutrophils and various
neutrophil-associated markers were significantly
reduced in lesional skinofplaquepsoriasis patients
after 1–2 weeks of treatment with secukinumab,
compared with baseline [40].
The pharmacokinetic (PK) profile of
secukinumab in patients with PsA is typical for
an IgG1 mAb and similar to that seen in
patients with psoriasis [40]. Based on
population PK analysis in patients with plaque
psoriasis, after initial weekly dosing during the
first month, time to reach the maximum
concentration of secukinumab was 31–34 days.
Based on simulated data, peak concentrations at
steady state (Cmax ss) following subcutaneous
(sc) administration of secukinumab 300 or
150 mg were estimated at 55.2 and 27.6 lg/
mL, respectively, after 20 weeks. Secukinumab
is absorbed with an average absolute
bioavailability of 73%, with a volume of
distribution of 7.10–8.60 L following a single
intravenous (i.v.) dose, suggesting that limited
distribution to peripheral compartments occurs.
Mean systemic clearance is 0.19 L/day, and is
not influenced by gender, dose, or time. The
mean elimination half-life of secukinumab in
patients with psoriasis is 27 days. In patients
with PsA, the bioavailability of secukinumab is
85%, and although clearance and volume of
distribution increase as body weight increases,
clearance is independent of age.
IL-17A
IL-17A
neutralized by
secukinumab
Secukinumab
(bound to IL-17A)
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hypersensitivity 
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Fig. 1 Secukinumab prevents IL-17A binding to its receptor, inhibiting production of pro-inﬂammatory mediators [54].
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Although no interaction studies have been
performed in humans, there is no evidence to
indicate that IL-17A will influence the
expression of CYP450 enzymes [40]. The
formation of some CYP450 enzymes is
suppressed by increased levels of cytokines
during chronic inflammation. Thus,
conceivably, agents targeting the IL-17
pathway may result in ‘normalization’ of
CYP450 levels with accompanying lower
exposure of CYP450-metabolized concomitant
medications. No interaction was seen when
secukinumab was administered together with
methotrexate (MTX) and/or corticosteroids in
PsA studies [40].
CLINICAL TRIALS
OF SECUKINUMAB IN PSA
In a small phase II proof-of-concept study in
patients with PsA, secukinumab showed
improvements in clinical response, C-reactive
protein (CRP) level, erythrocyte sedimentation
rate (ESR), and quality of life (QoL) measures
versus placebo, although it should be noted that
the primary endpoint, a C20% improvement
from baseline according to the American
College of Rheumatology 20 (ACR20) response
at Week 6, was not met [41]. Based on these
promising preliminary findings, two large,
randomized, placebo-controlled phase III
studies involving more than 1000 patients
with active PsA, FUTURE 1 (ClinicalTrials.gov
identifier: NCT01392326; [42]) and FUTURE 2
(ClinicalTrials.gov identifier: NCT01752634;
[43]), were subsequently initiated.
FUTURE 1 AND FUTURE 2
In FUTURE 1, patients with active PsA were
randomized (1:1:1) to one of three treatment
arms: i.v. secukinumab 10 mg/kg (weeks 0, 2,
4) followed by sc secukinumab 150 or 75 mg
every 4 weeks, or placebo (Fig. 2a). In FUTURE
2, patients were randomized (1:1:1:1) to one
of four arms: sc secukinumab 300, 150, 75 mg,
or placebo once a week from baseline to
Week 4 and then every 4 weeks thereafter
(Fig. 2b). In both studies, placebo patients
switched to sc secukinumab 150 or 75 mg at
Week 16 or 24, depending upon their clinical
response. In both FUTURE 1 and FUTURE 2,
patients who had an inadequate response to
TNF inhibitors (anti-TNF-IR), or who had not
previously received TNF inhibitors
(anti-TNF-naı¨ve), were eligible. At baseline,
approximately two-thirds of patients were
anti-TNF-naı¨ve and around half were
receiving concomitant MTX (Table 1). Both
studies are ongoing with FUTURE 1 planned
to run for 2 years followed by a 3-year
extension study and FUTURE 2 for the initial
52 weeks of study followed by an additional
4 years during which long-term efficacy and
safety data will be collected.
The primary endpoint in both FUTURE 1 and
FUTURE 2 was ACR20 response at Week 24 [42,
43]. This time point was chosen to align with
the assessment of radiographic progression
[modified total Sharp score (mTSS)] at Week 24
in the FUTURE 1 study and for consistency
across both studies. Other secondary endpoints
were Psoriasis Area Severity Index (PASI)75 and
PASI90, Disease Activity Score (DAS)28-CRP,
SF-36 Physical Component Summary (PCS)
score, Health Assessment Questionnaire
Disability Index (HAQ-DI), ACR50 response,
and presence of dactylitis and enthesitis.
Pre-specified exploratory endpoints included
ACR70 responses, additional patient-reported
outcomes and subgroup analyses according to
previous anti-TNF use.
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Key Results
Across FUTURE 1 and FUTURE 2, secukinumab
provided rapid and clinically meaningful
improvements in multiple facets of PsA,
including joint symptoms, skin symptoms,
dactylitis, and enthesitis. The primary and all
pre-defined secondary endpoints were met with
both secukinumab doses in FUTURE 1 (Figs. 3,
4, 5, 6, 7, 8, 9, 10) [42]. At Week 24, the ACR20
response rates were 50.0% with secukinumab
i.v.-150 mg, 50.5% with secukinumab
Loading
Secukinumab
10 mg/kg i.v.
Secukinumab
10 mg/kg i.v.
Week BL 2 4
R
1:1:1
Placebo i.v. Placebo s.c. 
Secukinumab 150 mg s.c. Wk16 then q4wk 
Secukinumab 75 mg s.c. Wk16 then q4wk
NON-RESPONDERS (<20% reduction in TJC and SJC)
Placebo s.c.
Secukinumab 150 mg s.c. Wk24 then q4wk 
Secukinumab 75 mg s.c. Wk24 then q4wk
RESPONDERS (≥20% reduction in TJC and/or SJC) 
R
1:1
R
1:1
Escape 
treatment
Treatment
8 12 16 20 24
Secukinumab 75 mg s.c.
Wk 8 then q4wk
Secukinumab 150 mg s.c.
Wk 8 then q4wk
104
Primary
endpoint
q4w
Secukinumab 150 mg s.c.
Wk 4 and q4wk
1 2 4 12 16 20 Wk 206 3Week 0
Secukinumab 75 mg s.c.
Wk 4 and q4wk
Secukinumab
75 mg s.c.
Wks 0,1,2,3 
Secukinumab 
150 mg s.c. 
Wks 0,1,2,3
Secukinumab 300 mg s.c.
Wk 4 and q4wk
Secukinumab
300 mg s.c.
Wks 0,1,2,3 
Placebo s.c.
Wks 0,1,2,3 
24
Placebo s.c.
Wks 4, 8, 12
Placebo s.c.
Wks 16, 20
Secukinumab 300 mg s.c.
Wk 24 and q4wk 
Secukinumab 150 mg s.c.
Wk 24 and q4wk
RESPONDERS (≥20% reduction in TJC and/or SJC)
Secukinumab 300 mg s.c.
Wk 16 and q4wk
Secukinumab 150 mg s.c.
Wk 16 and q4wk
NON-RESPONDERS (<20% reduction in TJC and SJC)
8
Loading Maintenance
Primary
endpoint
R
1:1
R
1:1
R
1:1:1:1
A
B
Fig. 2 Study designs of FUTURE 1 (a) and FUTURE 2 (b)
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i.v.-75 mg, and 17.3% with placebo (P\0.001
for both comparisons versus placebo; Fig. 3).
ACR50/70 responses at Week 24 were 34.7%/
18.8%, 30.7%/16.8%, and 7.4%/2.0%,
respectively (all P\0.001; Fig. 4). The clinical
improvements offered by secukinumab in
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Fig. 3 ACR20 responses from baseline to Week 24
(placebo-controlled period), and through Week 52
(observed) for patients randomized to secukinumab at
baseline. a Proportion of patients achieving ACR20 in
FUTURE 1. b Proportion of patients achieving ACR20 in
FUTURE 2. *P\0.0001; P\0.001; P\0.05 vs.
placebo (P values at Week 24 adjusted for multiplicity of
testing). Missing values were imputed as nonresponse
(nonresponder imputation) up to Week 24. Observed data
from Week 28–52 Figure 3a from The New England
Journal of Medicine. Mease PJ, McInnes IB, Kirkham B,
et al. 2015; 373:1329-1339. Copyright  2015
Massachusetts Medical Society. Reprinted with permission
from Massachusetts Medical Society
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FUTURE 1 were sustained with long-term
therapy. Applying a conservative estimate of
efficacy with missing values imputed as
non-response, ACR20 responses at Week 52
were 59.9% and 56.9%, respectively [42].
Observed values of ACR20 responses at
Week 52 were 69.5% with secukinumab
150 mg and 66.9% with secukinumab 75 mg
(Fig. 3). Two-year follow-up data from FUTURE
1 confirmed the sustainability of these effects
with long-term secukinumab treatment [42].
In FUTURE 2, the primary endpoint was met
with all secukinumab doses [43]. ACR20
response rates at Week 24 were 54.0% with
secukinumab 300 mg (P\0.0001), 51.0% with
150 mg (P\0.0001), and 29.3% with 75 mg
(P = 0.0399) versus 15.3% with placebo (Fig. 3).
Mean changes from baseline in DAS28-CRP and
SF36-PCS were all significantly improved with
secukinumab 300 and 150 mg versus placebo at
Week 24 (Figs. 7, 8). Secukinumab 300 mg also
significantly improved ACR50 and HAQ-DI
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versus placebo (Figs. 4, 9). Other endpoints were
not considered significant based on hierarchical
testing. ACR50 responses were achieved by
35.0%, 35.0%, and 18.2% of patients in the
secukinumab 300, 150, and 75 mg groups,
respectively, compared with 7.1% in the
placebo group (Fig. 4). The clinical
improvements induced by secukinumab in
FUTURE 2 were sustained through to Week 52;
response rates were 64.0%, 64.0%, and 50.5%
with missing values imputed as nonresponse in
the secukinumab 300, 150, and 75 mg groups,
respectively. Observed ACR20 responses were
73%, 73%, and 67%, respectively (Fig. 3) [43].
Psoriasis
Consistent with its clearly demonstrated effect
in primary cutaneous psoriasis phase III clinical
trials, secukinumab has been shown to
significantly improve the symptoms and signs
of both skin and nail psoriasis in patients with
PsA. Significant improvements were seen in
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PASI75/90 responses at Week 24 in both
FUTURE 1 and FUTURE 2 versus placebo
(Figs. 5, 6), with responses sustained for up to
52 weeks [42, 43]. Furthermore, improvements
in Investigator’s Global Assessment (IGA) 0/1
and mean Nail Psoriasis Severity Index (NAPSI)
scores, reductions in high-sensitivity C-reactive
protein (hsCRP) levels, and clinically
meaningful improvements (C4-point change
from baseline) in Dermatology Life Quality
Index (DLQI) were also seen with
secukinumab versus placebo at Week 24 in
both studies [44, 45].
Radiographic Progression
Secukinumab significantly inhibited
radiographic progression of PsA versus placebo
at Week 24 in FUTURE 1, as assessed by the
mTSS (Fig. 10), with this effect sustained
through 52 weeks of treatment [46].
Improvements in mTSS were reflected by
improvements in both the erosion and
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joint-space-narrowing scores (Fig. 10). Among
those patients who had initially received
placebo for the first 24 weeks then switched to
secukinumab, radiographic progression was also
inhibited. At Week 24, the proportion of
patients with no disease progression was
greater for the secukinumab groups compared
with placebo-treated patients (82.3% and 92.3%
for the i.v.-150 mg and i.v.-75 mg, respectively,
vs. 75.7% for the placebo group). This effect was
sustained in the secukinumab groups at
Week 52 (85.7% and 85.8%), and increased in
patients who were initially randomized to
placebo and then given active treatment
(86.8%).
Dactylitis and Enthesitis
In FUTURE 1, a significantly greater proportion
of patients achieved complete resolution of
dactylitis and enthesitis with secukinumab
(pooled doses; predefined secondary endpoint)
compared with placebo at Week 24. Exploratory
analysis of dactylitis and enthesitis resolution in
the individual dose arms of FUTURE 1 was
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consistent with the pooled analysis. In patients
with symptoms at baseline, 48.1% and 46.0% in
the i.v.-150 mg group and 56.7% and 48.8% in
the i.v.-75 mg group showed complete
resolution of dactylitis and enthesitis,
respectively, at Week 24, versus 15.5% and
12.8% with placebo (all P\0.0001). At
Week 52, 87.7% and 89.7% of patients in the
i.v.-150 mg and i.v.-75 mg groups, respectively,
were free from dactylitis compared with 48.5%
and 48.5% at baseline (Fig. 11); 81.6% and
79.4% were free from enthesitis at Week 52
versus 37.6% and 36.1% at baseline.
Although numerical improvements in the
proportion of patients achieving resolution of
dactylitis and enthesitis with pooled
secukinumab versus placebo were seen in
FUTURE 2, these changes were not statistically
significant when examined by a hierarchical
testing methodology. Nevertheless, exploratory
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analysis of dactylitis and enthesitis resolution
by individual doses indicated clinically
meaningful improvements in resolution with
secukinumab 300 mg and 150 mg versus
placebo at Week 24 [47]. In patients with
symptoms at baseline, 56.5% (P\0.01) and
48.2% (P\0.01) in the 300 mg group and
50.0% (P\0.01) and 42.2% (P\0.05) in the
150 mg group showed complete resolution of
dactylitis and enthesitis, respectively, at
Week 24, versus 14.8% and 21.5% with
placebo. At Week 52, 88.2% and 90.9% of
patients in the 300 and 150 mg groups,
respectively, were free from dactylitis
compared with 54.0% and 68.0% at baseline
(Fig. 11); 72.0% and 69.3% were free from
enthesitis at Week 52 versus 44.0% and 36.0%
at baseline. Secukinumab also reduced the
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number of dactylitic digits and enthesitis sites,
determined via multiple methods of assessment
at Week 24.
Patient-Reported Outcomes
Secukinumab also mediated a positive impact
on various patient-reported outcomes
including physical function, QoL and fatigue.
In FUTURE 1, SF-36 PCS and HAQ-DI were
significantly improved with both secukinumab
i.v.-150 mg and i.v.-75 mg versus placebo at
Week 24, while in FUTURE 2, SF-36 PCS was
significantly enhanced with secukinumab 300
and 150 mg and HAQ-DI was significantly
improved with secukinumab 300 mg (Figs. 8,
9). Exploratory analyses of several other
patient-reported outcomes in FUTURE 2 at
Week 24 also showed significant
improvements in fatigue, as measured by the
Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) scale, and QoL, as
measured by the Psoriatic Arthritis Quality of
Life (PsA QoL) score, for secukinumab versus
placebo [43, 48].
Efficacy of Secukinumab in Patient Subgroups
Pre-specified subgroup analyses of FUTURE 1
and FUTURE 2 showed clinical benefits with
secukinumab in patients who were anti-TNF
treatment-naı¨ve and patients who were prior
inadequate responders to anti-TNF
(TNFi-exposed). In both studies, significantly
greater proportions of patients achieved ACR
responses with secukinumab versus placebo
after 24 weeks in both subgroups [42, 43]. In
FUTURE 1, ACR20 response rates in the
TNF-naı¨ve subgroup using nonimputed data
(missing values were imputed as non-response
[non-responder imputation (NRI)] at Week-24
were 54.5% for secukinumab i.v.-150 mg and
55.6% for secukinumab i.v.-75 mg, compared
with 17.5% in the placebo group. At Week 52
using observed data, the ACR20 response rates
were 75.2% for secukinumab i.v.-150 mg and
73.2% for secukinumab i.v.-75 mg (Fig. 12a). In
the TNFi-exposed subgroup, the ACR20
responses at Week 24 were 39.0% and 38.3%
in the secukinumab i.v.-150 mg and i.v.-75 mg
groups, respectively, compared with 16.9% in
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the placebo group. The Week 52 observed data
were 53.3% for secukinumab i.v.-150 mg and
51.0% for secukinumab i.v.-75 mg (Fig. 12a).
Similarly, in FUTURE 2, ACR20 response
rates in the TNF-naı¨ve subgroup using
nonimputed data at Week 24 were 58.2% for
secukinumab 300 mg, 63.5% for secukinumab
150 mg, 36.9% for secukinumab 75 mg, and
15.9% in the placebo group. At Week 52 using
observed data, the ACR20 response rates were
79.4% for secukinumab 300 mg, 84.7% for
secukinumab 150 mg, and 67.9% for
48.5 48.5
*
*
104 104 116
46.0 48.8
12.8
100
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s 
80
60
20
0
100
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s 
80
60
20
0
FUTURE 1 FUTURE 1
40 40
FUTURE 2 FUTURE 2
* *
Resolution of Dactylitis at Week 24 
(Non-responder Imputation)
Resolution of Enthesitis at Week 24
(Non-responder Imputation)
126 129 117
Secukinumab 300 mg Secukinumab 75 mg PlaceboSecukinumab 150 mg
Secukinumab 300 mg Secukinumab 75 mgSecukinumab 150 mg
48.1
56.7
15.5
56.5
50.0
30.3
14.8
‡
46 32 33 27
48.2
42.2
32.4
21.5
‡
‡
56 64 68 65
37.6
81.6
36.1
79.4
0
20
40
60
80
100
Baseline Week 52
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s
FUTURE 1
202 202 179 175
87.7 89.7
0
20
40
60
80
100
Baseline Week 52
Pe
rc
en
ta
ge
 o
f P
at
ie
nt
s
FUTURE 1
202 202 179 175
54.0
88.2
68.0
90.9
66.3
88.3
Baseline Week 52
FUTURE 2
100 100 93 8898 77
44.0
72.0
36.0
69.3
30.6
63.6
Baseline Week 52
FUTURE 2
100 100 93 8898 77
Patients Without Dactylitis 
(Observed Data)
Patients Without Enthesitis 
(Observed Data)
A
B
Fig. 11 Resolution of enthesitis and dactylitis at Week 24
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secukinumab 75 mg (Fig. 12b). In the
TNFi-exposed subgroup, the ACR20 responses
at Week 24 were 45.5%, 29.7% and 14.7% in the
secukinumab 300, 150, and 75 mg groups,
respectively, compared with 14.3% in the
placebo group. The Week 52 observed data
were 62.1% for secukinumab 300 mg, 37.8%
for secukinumab 150 mg, and 63.2% for
secukinumab 75 mg (Fig. 12b).
Improvements with secukinumab versus
placebo were also seen in both subgroups in a
range of other endpoints, including PASI75/90,
DAS-28, and HAQ-DI [42, 43, 49]. The
magnitude of response was generally higher in
the anti-TNF-naı¨ve population [42, 43]. A dose
effect emerged in this context, analogous to
that observed in cutaneous psoriasis studies,
since secukinumab 300 mg was associated with
the greatest improvements in anti-TNF-IR
patients. The efficacy of secukinumab was
sustained for up to 52 weeks in both
subgroups [49]. Finally, it is worth noting that
in post hoc analyses, improvements in ACR
response rates with secukinumab compared
with placebo at Week 24 were similar
regardless of concomitant MTX use [42, 43].
Safety in Phase III Trials
Secukinumab was well-tolerated in patients
with active PsA across FUTURE 1 and FUTURE
2 (Table 2) [42, 43]. More than 1200 patients
were assessed for safety across the two FUTURE
trials, with a mean exposure to secukinumab of
438.5 days in FUTURE 1 and 411.7 days in
FUTURE 2 (Table 2). Among these patients, the
exposure-adjusted incidence rate of any adverse
event in the secukinumab-treated patients for
FUTURE 1 and FUTURE 2 was 471 and 307 per
100 patient-years, respectively (Table 2). Across
both studies, the most common adverse events
were nasopharyngitis, upper respiratory tract
infections, and headache (Table 2).
Serious adverse events were also uncommon
among secukinumab-treated patients.
Discontinuation due to adverse events
occurred in 23 (3.9%) secukinumab-treated
patients in FUTURE 1 and 8 (2.1%)
secukinumab-treated patients in FUTURE 2,
compared with 5 (2.5%) and 4 (4.1%) patients
in the placebo groups of FUTURE 1 and FUTURE
2, respectively.
Adverse events of special interest were
similar between groups in both studies
(Table 2). Three patients (0.7%) had Candida
infection in the FUTURE 1 study compared with
no patients in the placebo group in the first
16 weeks. In FUTURE 2, 2 patients (0.7%) had
Candida infection compared with no patients
in the placebo group. There was only one death,
due to intracranial venous sinus thrombosis in
FUTURE 1. Adverse events of inflammatory
bowel disease/Crohn’s disease were rare with
secukinumab. One patient in the placebo group
and one patient in the secukinumab group
experienced de novo events of Crohn’s disease
across the entire treatment period of FUTURE 1.
There were 12 cases of neutropenia in
secukinumab-treated patients across the entire
treatment period of FUTURE 1 and 5 cases in
secukinumab-treated patients in FUTURE 2; the
majority of events were transient Grade 1 or 2
neutropenia and there were no instances of
Grade 4 neutropenia. No patients withdrew
from either FUTURE 1 or FUTURE 2 because of
neutropenia. Incidences of major adverse
cardiac events and malignancy were also low
among secukinumab-treated patients. No
attempted or completed suicide or suicidal
Fig. 12 ACR20 and ACR50 response with secukinumab
by anti-TNF status in FUTURE 1 (a) and FUTURE 2
(b) at Week 24 and Week 52. Missing values were imputed
as non-response (non-responder imputation) at Week 24;
observed data are shown at Week 52. *P\0.0001;
P\0.001; P\0.05 vs. placebo
b
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ideation was reported in secukinumab-treated
patients across both studies.
Secukinumab has a low potential for
immunogenicity, as evidenced by the low
incidence of treatment-emergent anti-drug
antibodies (ADAs; i.e., tests that were positive
during the study but negative at baseline). In
FUTURE 1, while 3 out of 10 patients with ADAs
at baseline continued to have ADAs and
neutralizing antibodies in all or most
post-baseline samples, treatment-emergent
ADAs were detected in only one patient.
Similarly, in FUTURE 2 treatment-emergent
ADAs were detected in one patient who
switched to secukinumab 150 mg at week 24,
but no immunogenicity-related adverse events
or loss of efficacy were reported in this patient.
SECUKINUMAB IN THE PSA
TREATMENT PARADIGM
Although head-to-head trials would be required
to reach definite conclusions, indirect
comparisons suggest that secukinumab is at
least as effective as currently available therapies
mediated via an alternative mode of action.
Thus, secukinumab should be a useful addition
to the PsA treatment armamentarium. Indeed,
recent updates to treatment guidelines for PsA
presented by the European League Against
Rheumatism (EULAR) and the Group for
Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) have incorporated
anti-IL-17 therapy into their treatment
algorithms [11, 12]. Biologic therapy,
including anti-TNF agents (e.g., infliximab,
etanercept, certolizumab, golimumab and
adalimumab), anti-IL-12/23 (e.g.,
ustekinumab) and anti-IL-17 therapy (e.g.,
secukinumab) is recommended for patients
with inadequate response or intolerance to
NSAIDs and conventional synthetic DMARDs.
Biologics have demonstrated efficacy across PsA
clinical domains, including peripheral arthritis,
enthesitis, dactylitis, axial disease, or severe skin
disease occurring in combination, particularly if
the latter is dominant [11, 12].
Secukinumab (Cosentyx, Novartis) was
recently approved in Europe (October 2015)
and in the United States (January 2016) for the
treatment of active PsA. The secukinumab
clinical trial program is ongoing, including
three further phase 3 studies in PsA: FUTURE 3
(ClinicalTrials.gov identifier: NCT01989468) is
a 24-week study that will investigate the safety
and efficacy of subcutaneous secukinumab 300
and 150 mg versus placebo; FUTURE 4
(ClinicalTrials.gov identifier: NCT02294227) is
a 16-week study that will assess the efficacy and
safety of subcutaneous secukinumab 150 mg
versus placebo with or without a loading
regimen; and FUTURE 5 (ClinicalTrials.gov
identifier: NCT02404350) will investigate the
effect of subcutaneous secukinumab 150 and
300 mg on progression of structural damage for
up to 2 years.
Currently, secukinumab is also the only
IL-17A inhibitor approved as a first-line
systemic treatment for moderate to severe
plaque psoriasis in adult patients in Europe,
and as a treatment for moderate to severe
plaque psoriasis in adult patients who are
candidates for systemic therapy or
phototherapy in the US. Secukinumab has also
been approved in Switzerland, Chile, Australia,
Argentina, Canada, Japan, and Singapore for
the treatment of moderate to severe plaque
psoriasis. Approval was granted based on the
significant efficacy shown with secukinumab in
improving the signs and symptoms of psoriasis
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compared with placebo, etanercept, and
ustekinumab in phase III trials [50, 51].
Secukinumab is being investigated across
other rheumatic diseases. In patients with
active ankylosing spondylitis (AS),
secukinumab rapidly and significantly
improved the signs and symptoms of disease
versus placebo in two phase III trials [52] and
was recently approved for the treatment of AS
by the EMA and FDA. To our knowledge it is not
being developed as a mono-biologic for patients
with rheumatoid arthritis.
CONCLUSIONS
Secukinumab is the first anti-IL-17A therapy to
demonstrate efficacy in phase 3 clinical trials in
PsA. In more than 1000 patients across FUTURE
1 and FUTURE 2, significant efficacy was
demonstrated with secukinumab versus
placebo in all components of PsA including
joint symptoms, skin symptoms, dactylitis,
enthesitis, and patient-reported outcomes,
with responses sustained up to 52 weeks.
Furthermore, no radiographic disease
progression was observed in more than 80% of
the patients receiving secukinumab. Efficacy
was demonstrated regardless of concomitant
MTX therapy and in both anti-TNF-IR patients
and those naı¨ve to anti-TNF therapies. The
safety profile of secukinumab was consistent
with previous studies in psoriasis, with no new
or unexpected safety findings identified.
These results highlight the important role
played by IL-17A in the pathogenesis of PsA,
and together with the positive results from
recent studies in AS [53], suggest that
secukinumab will be a valuable addition to
the available treatment options for PsA and
other chronic and disabling rheumatic
diseases.
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